Earlier this month, Gilead announced that it will commence Phase I clinical trials for inhaled remdesivir in healthy volunteers, with the aim to extend further studies in patients with Covid-19 in the following months. This follows previous studies highlighting that intravenously administered remdesivir did not provide a meaningful benefit to milder Covid-19 patients. Despite this, an inhaled formulation might work in a different manner.
GlobalData forecasts that the inhaled formulation will target this population, administered by way of a nebuliser for patients to self-administer away from hospitals so staff can prioritise beds for more critical patients. Read more here.